Haemonetics Corp Mass Financials
This page shows Haemonetics Corp Mass (HAE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin expansion is carrying earnings faster than sales, while buybacks and added leverage are tightening the balance sheet.
Between FY2024 and FY2025, revenue grew only4.0% while operating income rose34.5% , pointing to margin expansion rather than top-line acceleration as the main earnings engine. Even with net income at$167.7M , equity shrank because$225M of buybacks absorbed more than the year’s retained profit, which helps explain why leverage moved up instead of down.
The business looks less capital-intensive than it did in FY2023: free cash flow stayed near
Cash generation did not scale as cleanly as profit: FY2025 operating cash flow was
Financial Health Signals
Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Haemonetics Corp Mass's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Haemonetics Corp Mass has an operating margin of 11.8%, meaning the company retains $12 of operating profit per $100 of revenue. This results in a moderate score of 52/100, indicating healthy but not exceptional operating efficiency. This is down from 16.3% the prior year.
Haemonetics Corp Mass's revenue declined 2% year-over-year, from $1.4B to $1.3B. This contraction results in a growth score of 35/100.
Haemonetics Corp Mass carries a low D/E ratio of 1.53, meaning only $1.53 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 71/100, indicating a strong balance sheet with room for future borrowing.
Haemonetics Corp Mass's current ratio of 2.95 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.
Haemonetics Corp Mass has a free cash flow margin of 19.5%, earning a moderate score of 63/100. The company generates positive cash flow after capital investments, but with room for improvement.
Haemonetics Corp Mass's ROE of 12.2% shows moderate profitability relative to equity, earning a score of 44/100. This is down from 20.4% the prior year.
Haemonetics Corp Mass scores 2.49, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($3.4B) relative to total liabilities ($1.6B). This signals moderate financial risk that warrants monitoring.
Haemonetics Corp Mass passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Haemonetics Corp Mass generates $3.01 in operating cash flow ($293.2M OCF vs $97.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Haemonetics Corp Mass earns $8.1 in operating income for every $1 of interest expense ($156.7M vs $19.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Haemonetics Corp Mass generated $1.3B in revenue in fiscal year 2026. This represents a decrease of 2.0% from the prior year.
Haemonetics Corp Mass's EBITDA was $268.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.4% from the prior year.
Haemonetics Corp Mass reported $97.3M in net income in fiscal year 2026. This represents a decrease of 42.0% from the prior year.
Haemonetics Corp Mass earned $2.05 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 38.1% from the prior year.
Cash & Balance Sheet
Haemonetics Corp Mass generated $260.4M in free cash flow in fiscal year 2026, representing cash available after capex. This represents an increase of 82.8% from the prior year.
Haemonetics Corp Mass held $245.4M in cash against $1.2B in long-term debt as of fiscal year 2026.
Haemonetics Corp Mass had 45M shares outstanding in fiscal year 2026. This represents a decrease of 5.7% from the prior year.
Margins & Returns
Haemonetics Corp Mass's gross margin was 59.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 4.0 percentage points from the prior year.
Haemonetics Corp Mass's operating margin was 11.8% in fiscal year 2026, reflecting core business profitability. This is down 4.6 percentage points from the prior year.
Haemonetics Corp Mass's net profit margin was 7.3% in fiscal year 2026, showing the share of revenue converted to profit. This is down 5.0 percentage points from the prior year.
Haemonetics Corp Mass's ROE was 12.2% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 8.2 percentage points from the prior year.
Capital Allocation
Haemonetics Corp Mass invested $59.8M in research and development in fiscal year 2026. This represents a decrease of 4.7% from the prior year.
Haemonetics Corp Mass spent $175.0M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 22.2% from the prior year.
Haemonetics Corp Mass invested $32.8M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 16.5% from the prior year.
HAE Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $346.4M+2.2% | $339.0M+3.6% | $327.3M+1.8% | $321.4M-2.8% | $330.6M-5.1% | $348.5M+0.9% | $345.5M+2.8% | $336.2M |
| Cost of Revenue | $148.1M+8.5% | $136.6M+3.0% | $132.6M+2.6% | $129.2M-6.1% | $137.5M-11.3% | $155.0M-1.9% | $158.1M-2.0% | $161.2M |
| Gross Profit | $198.2M-2.1% | $202.4M+3.9% | $194.7M+1.3% | $192.2M-0.4% | $193.1M-0.3% | $193.5M+3.3% | $187.4M+7.2% | $174.9M |
| R&D Expenses | $14.4M+1.8% | $14.2M-4.6% | $14.9M-8.5% | $16.3M-11.2% | $18.3M+15.6% | $15.8M+12.0% | $14.1M-2.1% | $14.4M |
| SG&A Expenses | $120.9M+10.8% | $109.2M+7.4% | $101.6M-8.2% | $110.7M-3.8% | $115.1M+8.2% | $106.5M-0.5% | $106.9M-1.2% | $108.2M |
| Operating Income | -$23.0M-134.2% | $67.4M+15.2% | $58.5M+8.6% | $53.9M-24.5% | $71.3M+20.8% | $59.0M+14.2% | $51.7M+30.0% | $39.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | -$8.3M-154.2% | $15.2M+20.9% | $12.6M+13.1% | $11.1M-12.7% | $12.8M+2.7% | $12.4M+14.3% | $10.9M+30.4% | $8.3M |
| Net Income | -$20.1M-145.0% | $44.7M+15.7% | $38.7M+13.7% | $34.0M-41.3% | $58.0M+54.6% | $37.5M+10.8% | $33.8M-11.8% | $38.4M |
| EPS (Diluted) | N/A | $0.95+17.3% | $0.81+15.7% | $0.70 | N/A | $0.74+12.1% | $0.66-10.8% | $0.74 |
HAE Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.4B-3.8% | $2.5B+2.0% | $2.4B-0.8% | $2.5B+0.5% | $2.5B-3.2% | $2.5B+0.2% | $2.5B-0.6% | $2.5B |
| Current Assets | $834.9M-11.5% | $943.7M+4.9% | $899.7M-1.5% | $913.2M-2.3% | $935.0M-7.0% | $1.0B+5.2% | $955.9M-2.3% | $978.6M |
| Cash & Equivalents | $245.4M-32.5% | $363.4M+22.6% | $296.4M+1.2% | $292.9M-4.5% | $306.8M-4.4% | $320.8M+7.2% | $299.3M-13.1% | $344.4M |
| Inventory | $306.4M-4.6% | $321.2M-4.5% | $336.2M-6.7% | $360.5M-1.3% | $365.1M+1.5% | $359.6M-5.9% | $382.1M+2.2% | $373.8M |
| Accounts Receivable | $216.9M+10.8% | $195.7M-5.5% | $207.1M+3.1% | $200.8M-0.9% | $202.7M-4.4% | $211.9M-0.7% | $213.5M+6.0% | $201.5M |
| Goodwill | $656.4M+8.2% | $606.8M+0.1% | $606.1M-0.2% | $607.3M+0.5% | $604.3M-0.2% | $605.3M-1.8% | $616.2M+0.5% | $613.3M |
| Total Liabilities | $1.6B+1.3% | $1.6B-0.9% | $1.6B+0.8% | $1.6B-3.1% | $1.6B+0.4% | $1.6B-1.3% | $1.6B+0.7% | $1.6B |
| Current Liabilities | $282.6M-47.7% | $539.9M-1.5% | $548.3M+3.2% | $531.4M-8.1% | $578.1M+128.3% | $253.2M-7.6% | $273.9M+5.3% | $260.1M |
| Long-Term Debt | $1.2B+32.6% | $920.0M0.0% | $920.4M0.0% | $920.8M0.0% | $921.2M-24.5% | $1.2B0.0% | $1.2B+0.1% | $1.2B |
| Total Equity | $796.3M-12.6% | $911.5M+7.3% | $849.2M-3.8% | $882.3M+7.5% | $820.8M-9.5% | $906.9M+3.2% | $878.9M-2.9% | $905.4M |
| Retained Earnings | $279.3M-26.7% | $381.1M+13.3% | $336.3M-5.5% | $356.0M+1.1% | $352.2M-10.2% | $392.2M+6.4% | $368.5M-4.7% | $386.6M |
HAE Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $70.9M-24.2% | $93.6M-16.0% | $111.3M+540.0% | $17.4M-85.1% | $116.6M+166.3% | $43.8M-10.4% | $48.8M+278.0% | -$27.4M |
| Capital Expenditures | $17.7M+178.2% | $6.3M+26.6% | $5.0M+33.6% | $3.8M-76.0% | $15.6M+83.0% | $8.5M-9.4% | $9.4M+66.8% | $5.7M |
| Free Cash Flow | $53.3M-38.9% | $87.2M-18.0% | $106.3M+679.3% | $13.6M-86.5% | $100.9M+186.5% | $35.2M-10.6% | $39.4M+219.1% | -$33.1M |
| Investing Cash Flow | -$86.6M-193.9% | -$29.5M+3.3% | -$30.5M+7.7% | -$33.0M-282.9% | $18.0M+203.9% | -$17.4M+25.7% | -$23.4M+83.2% | -$139.2M |
| Financing Cash Flow | -$101.5M-5092.6% | $2.0M+102.7% | -$76.6M-3034.8% | -$2.4M+98.4% | -$151.4M-11074.6% | $1.4M+101.8% | -$74.8M-122.4% | $333.7M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $100.0M | $0 | N/A | N/A | $150.0M | $0 | N/A | N/A |
HAE Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.2%-2.5pp | 59.7%+0.2pp | 59.5%-0.3pp | 59.8%+1.4pp | 58.4%+2.9pp | 55.5%+1.3pp | 54.3%+2.2pp | 52.0% |
| Operating Margin | -6.7%-26.5pp | 19.9%+2.0pp | 17.9%+1.1pp | 16.8%-4.8pp | 21.6%+4.6pp | 16.9%+2.0pp | 15.0%+3.1pp | 11.8% |
| Net Margin | -5.8%-19.0pp | 13.2%+1.4pp | 11.8%+1.2pp | 10.6%-7.0pp | 17.5%+6.8pp | 10.8%+1.0pp | 9.8%-1.6pp | 11.4% |
| Return on Equity | -2.5%-7.4pp | 4.9%+0.3pp | 4.6%+0.7pp | 3.9%-3.2pp | 7.1%+2.9pp | 4.1%+0.3pp | 3.9%-0.4pp | 4.2% |
| Return on Assets | -0.8%-2.6pp | 1.8%+0.2pp | 1.6%+0.2pp | 1.4%-1.0pp | 2.4%+0.9pp | 1.5%+0.1pp | 1.3%-0.2pp | 1.5% |
| Current Ratio | 2.95+1.2 | 1.75+0.1 | 1.64-0.1 | 1.72+0.1 | 1.62-2.4 | 3.97+0.5 | 3.49-0.3 | 3.76 |
| Debt-to-Equity | 1.53+0.5 | 1.01-0.1 | 1.08+0.0 | 1.04-0.1 | 1.12-0.2 | 1.34-0.0 | 1.39+0.0 | 1.35 |
| FCF Margin | 15.4%-10.3pp | 25.7%-6.8pp | 32.5%+28.2pp | 4.2%-26.3pp | 30.5%+20.4pp | 10.1%-1.3pp | 11.4%+21.2pp | -9.8% |
Similar Companies
Frequently Asked Questions
What is Haemonetics Corp Mass's annual revenue?
Haemonetics Corp Mass (HAE) reported $1.3B in total revenue for fiscal year 2026. This represents a -2.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Haemonetics Corp Mass's revenue growing?
Haemonetics Corp Mass (HAE) revenue declined by 2% year-over-year, from $1.4B to $1.3B in fiscal year 2026.
Is Haemonetics Corp Mass profitable?
Yes, Haemonetics Corp Mass (HAE) reported a net income of $97.3M in fiscal year 2026, with a net profit margin of 7.3%.
What is Haemonetics Corp Mass's EBITDA?
Haemonetics Corp Mass (HAE) had EBITDA of $268.5M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Haemonetics Corp Mass have?
As of fiscal year 2026, Haemonetics Corp Mass (HAE) had $245.4M in cash and equivalents against $1.2B in long-term debt.
What is Haemonetics Corp Mass's gross margin?
Haemonetics Corp Mass (HAE) had a gross margin of 59.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Haemonetics Corp Mass's operating margin?
Haemonetics Corp Mass (HAE) had an operating margin of 11.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Haemonetics Corp Mass's net profit margin?
Haemonetics Corp Mass (HAE) had a net profit margin of 7.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Haemonetics Corp Mass's return on equity (ROE)?
Haemonetics Corp Mass (HAE) has a return on equity of 12.2% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Haemonetics Corp Mass's free cash flow?
Haemonetics Corp Mass (HAE) generated $260.4M in free cash flow during fiscal year 2026. This represents a 82.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Haemonetics Corp Mass's operating cash flow?
Haemonetics Corp Mass (HAE) generated $293.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Haemonetics Corp Mass's total assets?
Haemonetics Corp Mass (HAE) had $2.4B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Haemonetics Corp Mass's capital expenditures?
Haemonetics Corp Mass (HAE) invested $32.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Haemonetics Corp Mass spend on research and development?
Haemonetics Corp Mass (HAE) invested $59.8M in research and development during fiscal year 2026.
What is Haemonetics Corp Mass's current ratio?
Haemonetics Corp Mass (HAE) had a current ratio of 2.95 as of fiscal year 2026, which is generally considered healthy.
What is Haemonetics Corp Mass's debt-to-equity ratio?
Haemonetics Corp Mass (HAE) had a debt-to-equity ratio of 1.53 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Haemonetics Corp Mass's return on assets (ROA)?
Haemonetics Corp Mass (HAE) had a return on assets of 4.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Haemonetics Corp Mass's Altman Z-Score?
Haemonetics Corp Mass (HAE) has an Altman Z-Score of 2.49, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Haemonetics Corp Mass's Piotroski F-Score?
Haemonetics Corp Mass (HAE) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Haemonetics Corp Mass's earnings high quality?
Haemonetics Corp Mass (HAE) has an earnings quality ratio of 3.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Haemonetics Corp Mass cover its interest payments?
Haemonetics Corp Mass (HAE) has an interest coverage ratio of 8.1x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Haemonetics Corp Mass?
Haemonetics Corp Mass (HAE) scores 53 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.